Claims
- 1. A method for reducing or preventing tissue adhesions comprising the application to a tissue of a tissue glue, wherein the tissue glue comprises:
a stabilized fibrinogen preparation, and a thrombin preparation, wherein the fibrinogen preparation can be stored in the liquid or frozen state, wherein the fibrinogen preparation further comprises a chaotropic substance in the range of more than about 0.04 M to less than about 0.28 M, and wherein the tissue glue reduces or prevents tissue adhesions.
- 2. The method according to claim 1, wherein the tissue glue further comprises a preparation comprising coagulation Factor XIII.
- 3. The method according to one of claims 1 or 2, wherein the tissue glue further comprises an antifibrinolytic agent.
- 4. The method according to claim 3, wherein the antifibrinolytic agent is ε-aminocaproic acid.
- 5. The method according to claim 3, wherein the antifibrinolytic agent is p-aminomethylbenzoic acid.
- 6. The method according to claim 3, wherein the antifibrinolytic agent is aprotinin.
- 7. The method according to one of claims 1 or 2, wherein the preparation of the fibrinogen preparation comprises purification steps.
- 8. The method according to claim 7, wherein the fibrinogen preparation has a reduced plasminogen content.
- 9. The method according to claim 8, wherein the ratio of plasminogen to fibrinogen is less than 1.8×10−4 (W/W).
- 10. The method according to claim 2, wherein the Factor XIII preparation further comprises one or more substances selected from stabilizers or buffer substances.
- 11. The method according to claim 10, wherein the one or more stabilizers are selected from physiologically tolerated salts of an organic di-, tri- and tetracarboxylic acid.
- 12. The method according to claim 11, wherein the carboxylic acid is citric acid.
- 13. The method according to claim 10, wherein the Factor XIII preparation further comprises one or more stabilizers selected from:
a mono- or disaccharide or a sugar alcohol, at least one amino acid selected from glycine, glycylglycine, alanine, cysteine, histidine, glutamine or a physiologically tolerated salt of glutamic or aspartic acid, a reducing or oxidation-preventing agent, and a surface-active substance.
- 14. The method according to one of claims 1 or 2, wherein the one or more chaotropic substances is selected from arginine, guanidine, citrulline, urea, nicotine amide, and their derivatives.
- 15. The method according to one of claims 1 or 2, wherein the fibrinogen preparation further comprises one or more stabilizers selected from:
an inorganic salt, one or more physiologically tolerated salts of organic carboxylic acids, one or more amino acids, a mono- or disaccharide, and a sugar alcohol.
- 16. The method according to claim 15, wherein the carboxylic acid is selected from citric acid and lactic acid.
- 17. The method according to one of claims 1 or 2, wherein the thrombin preparation further comprises one or more stabilizers.
- 18. The method according to claim 17, wherein the one or more stabilizers are selected from:
a soluble calcium salt, sodium chloride, a buffer substance, a sugar, a sugar alcohol, an amino acid, a salt of a mono- or polycarboxylic acid, and a salt of a mono- or polyhydroxy carboxylic acid.
- 19. The method according to claim 17, wherein the stabilizer is a non-covalently binding inhibitor.
- 20. The method according to one of claims 1 or 2, wherein the preparation of the thrombin preparation comprises purification by hydrophobic interaction chromatography.
- 21. The method according to claim 20, wherein the purification of the thrombin preparation further comprises purification by cation exchange chromatography.
- 22. The method according to one of claims 1 or 2, wherein the tissue glue or the constituents of the tissue glue have been subjected to one or more methods for inactivating or removing viruses.
- 23. The method according to claim 3, wherein the tissue glue or the constituents of the tissue glue have been subjected to one or more methods for inactivating or removing viruses.
- 24. A method for reducing or preventing tissue adhesions comprising the application to a tissue of a tissue glue, wherein the tissue glue comprises:
a stabilized fibrinogen preparation, a thrombin preparation, wherein the fibrinogen preparation can be stored in the liquid or frozen state, wherein the fibrinogen preparation has a reduced plasminogen content, and wherein the tissue glue reduces or prevents tissue adhesions.
- 25. The method according to claim 1, wherein the tissue has optionally been treated with a conventional tissue glue prior to the application of the tissue glue of claim 1.
- 26. The method according to claim 24, wherein the tissue has optionally been treated with a conventional tissue glue prior to the application of the tissue glue of claim 24.
Priority Claims (2)
Number |
Date |
Country |
Kind |
100 25 001.7 |
May 2000 |
DE |
|
198 53 033.1 |
Nov 1998 |
DE |
|
Parent Case Info
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/856,195, filed on Jul. 13, 2001, and U.S. patent application Ser. No. 09/861,657, filed on May 22, 2001, and claims priority to both applications. This application also claims priority under 35 U.S.C. § 119 of German Patent Application No. 100 25 001.7, filed on May 22, 2000, and of German Patent Application No. 198 53 033.1, filed Nov. 18, 1998, both of which are hereby incorporated by reference.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09856195 |
Jul 2001 |
US |
Child |
10199018 |
Jul 2002 |
US |
Parent |
09861657 |
May 2001 |
US |
Child |
10199018 |
Jul 2002 |
US |